Despite of those experimental studies that strongly support CCL2 as a pro-tumorigenic role in breast cancer, therapeutics aimed at interfering CCL2-CCR2 axis have turned out to be disappointing in the clinical trials17–19. This evidence concerns the gene CCL2 and breast cancer.